Compare Lowe`s Companies Inc (LOW) vs Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Lowe`s Companies Inc vs Maravai LifeSciences Holdings Inc. Class A Common Stock — how do they compare? Lowe`s Companies Inc trades at $191 (market cap $105.89B), while Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $972.90M). The key difference: Lowe`s Companies Inc is far larger — about 108.8× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and Lowe`s Companies Inc pays a 2.65% dividend while Maravai LifeSciences Holdings Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Lowe`s Companies Inc for 98 Days and Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days on average.
| LOW | MRVI | |
|---|---|---|
Market Cap | $105.89B | $972.90M |
Volume | 3,104,115 | 4,325,710 |
Sector | Consumer Cyclical | Health |
52-Week High | $287.39 | $9.00 |
52-Week Low | $179.50 | $2.83 |
Typical Hold Time | 98 Days | 0 Days |
Enterprise Value | $144.74B | $1.08B |
Dividend Yield | 2.65% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Lowe's (LOW) trades at $188.36, up 1.5% with recent earnings beats but facing industry headwinds. The stock shows bearish technical signals despite positive analyst sentiment with a $244.09 consensus target. Revenue declined to $83.67B in 2025, though net margins remain healthy at 7.35%. Recent drone delivery initiatives with DoorDash and Alphabet aim to enhance competitiveness amid a challenging home improvement market.
LOW presents a value opportunity with reasonable P/E (15.95) and strong cash flow, but risks include declining revenue trends, high debt levels, and housing market sensitivity. Wall Street maintains bullish ratings (61% buy) despite near-term pressure, suggesting potential upside if execution improves.
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Lowe`s Companies Inc
Lowe's is the second-largest home improvement retailer in the world, operating 1,969 stores and servicing around 230 dealer-owned stores throughout the United States and Canada. The firm's stores offer products and services for home decorating, maintenance, repair, and remodeling, with maintenance and repair accounting for two thirds of products sold. Lowe's targets retail do-it-yourself (around 75% of sales) and do-it-for-me customers as well as commercial and professional business clients (around 25% of sales). We estimate Lowe's captures a low-double-digit share of the domestic home improvement market, based on U.S. Census data and management's estimates for market size.
Read more on LOW →About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →
